RBC Europe’s GSK GSK Stock Holding History

RBC Europe’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$94K	Hold	1,724	–	–	﹤0.01%	264
2022 Q1	$94K	Hold	1,724	–	–	﹤0.01%	288
2021 Q4	$95K	Buy	1,724 +300	+21%	+$15.6K	﹤0.01%	289
2021 Q3	$68K	Sell	1,424 -432	-23%	-$21.7K	﹤0.01%	509
2021 Q2	$92.4K	Hold	1,856	–	–	﹤0.01%	448
2021 Q1	$82.8K	Hold	1,856	–	–	﹤0.01%	443
2020 Q4	$85.4K	Sell	1,856 -96	-5%	-$4.41K	﹤0.01%	416
2020 Q3	$91.8K	Hold	1,952	–	–	0.01%	362
2020 Q2	$99.5K	Sell	1,952 -96	-5%	-$4.92K	0.01%	332
2020 Q1	$97K	Hold	2,048	–	–	0.01%	303
2019 Q4	$120K	Hold	2,048	–	–	0.01%	313
2019 Q3	$109K	Hold	2,048	–	–	0.01%	319
2019 Q2	$102K	Hold	2,048	–	–	0.01%	333
2019 Q1	$107K	Hold	2,048	–	–	0.01%	319
2018 Q4	$97.8K	Hold	2,048	–	–	0.01%	312
2018 Q3	$103K	Sell	2,048 -320	-14%	-$16.3K	0.01%	340
2018 Q2	$119K	Hold	2,368	–	–	0.01%	326
2018 Q1	$116K	Buy	2,368 +528	+29%	+$24.6K	0.01%	325
2017 Q4	$81.6K	Hold	1,840	–	–	0.01%	382
2017 Q3	$93.4K	Buy	+1,840	New	+$93.3K	0.01%	369

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

RBC Europe's GSK Position: Q2 2022 in Review

RBC Europe held its GSK (GSK) position steady in Q2 2022 at 1,724 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #264.

RBC Europe first reported a position in GSK in Q3 2017 and has held it in 20 quarters since. The position peaked at $120K in Q4 2019. 901 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

RBC Europe held 1,724 shares of GSK worth $94K as of Q2 2022.
RBC Europe left its GSK share count unchanged in Q2 2022.
GSK made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #264 holding.
RBC Europe first reported a position in GSK in Q3 2017 and has held it in 20 quarters since.
RBC Europe's GSK position peaked at $120K in Q4 2019.
901 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.